Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
Jun-Rui Chen(Huashan Hospital), Zhiyong Qin(Huashan Hospital), Yu Yao(Qinghai University), Hongzhi Xu(Huashan Hospital)
Cited by 139
Related Papers
CGCG clinical practice guidelines for the management of adult diffuse gliomas
|Cancer Letters|2016|650
Clinical practice guidelines for the management of adult diffuse gliomas
|Cancer Letters|2020|482
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
|The Lancet Oncology|2016|374
Temozolomide-associated hypermutation in gliomas
|Neuro-Oncology|2018|227
Adult IDH wild-type lower-grade gliomas should be further stratified
|Neuro-Oncology|2017|222